Sanofi and Alphabet’s life sciences firm Verily are investing about $500M in a diabetes joint venture combining devices with services, an example of growing ties between the pharma and tech sectors. “The company will leverage Verily’s (GOOG, GOOGL) experience in miniaturized electronics, analytics, and consumer software development, with Sanofi’s (NYSE:SNY) clinical expertise and experience,” the two companies said in a statement.
Bloomberg (12 Sept)
